Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Melanoma.

J E Gershenwald1

  • 1The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. jgershen@mdanderson.org

The Oncologist
|October 25, 2001
PubMed
Summary
This summary is machine-generated.

Advances in melanoma treatment were presented at the 2001 American Society of Clinical Oncology meeting. Key findings include sentinel lymph node status, interferon trials, biochemotherapy for advanced melanoma, and novel vaccine therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Sentinel node biopsy for primary cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.

The British journal of dermatology·2021
Same author

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Trials
  • Melanoma Research

Background:

  • The American Society of Clinical Oncology 2001 meeting highlighted significant advancements in melanoma management.
  • Presentations included phase I, II, and III randomized trials, meta-analyses, and retrospective studies.

Framework:

  • Early-stage melanoma: Prognostic significance of sentinel lymph node pathologic status was reaffirmed.
  • Regional nodal involvement (AJCC stage III): Interim results of the UK low-dose interferon trial and meta-analyses of interferon adjuvant therapy were presented.
  • Advanced disease (AJCC stage IV): Studies explored biochemotherapy for metastatic melanoma, focusing on central nervous system response and durability.

Implementation:

  • Novel chemopreventive potential of lovastatin for melanoma was investigated.

Related Experiment Videos

  • Translational research emphasized HLA-typing for targeted vaccine development.
  • An experimental melanoma vaccine utilizing autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) was presented.

    • Implications:

    • Findings impact the management of early-stage, regional, and advanced melanoma.
    • New therapeutic strategies, including targeted vaccines and potential chemopreventive agents, are emerging.
    • Continued research in interferon therapy and biochemotherapy may refine treatment protocols.